These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 22125944

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Redefining response in overactive bladder syndrome.
    Payne CK, Kelleher C.
    BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L, Thorpe A, Warner J, Sidhu M.
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
    Nitti VW, Rovner ES, Bavendam T.
    BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
    Wang AC, Chih SY, Chen MC.
    Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
    Thiagamoorthy G, Giarenis I, Cardozo L.
    Expert Opin Investig Drugs; 2015 Nov; 24(10):1299-306. PubMed ID: 26292923
    [Abstract] [Full Text] [Related]

  • 33. The medical management of refractory overactive bladder.
    Robinson D, Giarenis I, Cardozo L.
    Maturitas; 2013 Apr; 74(4):386-90. PubMed ID: 23395402
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
    Lee KS, Lee HW, Choo MS, Paick JS, Lee JG, Seo JT, Lee JZ, Lee YS, Yoon H, Park CH, Na YG, Jeong YB, Lee JB, Park WH.
    BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS, Elinoff V, Gordon DA, Deng DY, Brodsky M, Glasser DB, Jumadilova Z, Carlsson M.
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.